Regen BioPharma, Inc. is a publicly traded biotechnology company based in La Mesa, CA, dedicated to improving the quality of life through the development of cutting-edge medical technologies for the treatment of cancer and autoimmune disorders. Their focus lies in the advancement of therapies that modulate the immune checkpoint NR2F6, as well as the development of small molecules and gene silencing techniques for treating blood disorders and repairing damaged bone marrow.
With a diverse pre-clinical pipeline of cell therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, Regen BioPharma is at the forefront of innovative treatments in the field of immune-oncology and autoimmunity. Their technologies are protected by multiple granted and pending patents, ensuring the company's commitment to pioneering advancements in medical technology.
Generated from the website